Aardvark Therapeutics (AARD)

• Market cap: $144M
• 1 day: 7.86%
• 5 days: 14.41%
• 1 month: 64.34%
• 3 months: -45.54%
• 6 months: -39.32%
• Year to date: -50.04%
• 1 year: -35.01%
• 5 years: -53.95%
• 10 years: -53.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 40